ClinicalTrials.gg
CompletedNCT07566572Updated Oct 13, 2026

A Study of BGM0504 Tablets in Healthy Chinese Subjects

A Phase 1 interventional study of BGM0504 tablets in Chinese Healthy Volunteers, sponsored by BrightGene Bio-Medical Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by BrightGene Bio-Medical Technology Co., Ltd. · Phase 1, Interventional, and Basic science

Updated Oct 13, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
144
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Study summary

A randomized, open-label, multiple-dose study to evaluate the effects of high-fat meals and different administration conditions (including water intake and fasting time) on the pharmacokinetics of BGM0504 tablets at a dose of 20mg in healthy Chinese participants and to assess its safety and tolerability.

02

Conditions studied

  • Chinese Healthy Volunteers
03

In context

Lead sponsor

BrightGene Bio-Medical Technology Co., Ltd. is the lead sponsor of 18 studies on the registry; 3 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ○ Between the ages of 18 and 55 years (inclusive) at the time of screening, both male and female;

    • weight ≥ 50 kg, and (BMI): 24.0 kg/m² ≤ BMI \< 30 kg/m²(BMI = weight/height²);
    • (Medical Inquiry) Have a stable body weight (\<5% self-reported change during the previous 12 weeks) before screening.
    • Participants should be willing to take effective measures from the date of signing the form until 3 months after the last administration, and have no plans for sperm or egg donation.
    • Participants who were determined to be generally healthy by the investigator based on their past medical history, physical examination, vital signs, laboratory tests and examinations.

Exclusion criteria

Exclusion Criteria:

  • ● (Medical Inquiry) Individuals with a history of severe drug allergies (especially known or suspected allergies to the components and of BGM0504 tablets) or those with severe specific allergic diseases/diseases history or severe allergic constitution;

    • (Medical Inquiry) Individuals who have previously suffered from or currently have major diseases in the nervous system, cardiovascular system, digestive system, respiratory system, urinary system, endocrine system, blood system or immune system, and are judged by the investigator to be unsuitable to participate in this trial;
    • (Examination) Any laboratory test results judged by the investigator as abnormal and of clinical significance;
    • (Medical Inquiry/Examination) Individuals who previously had obvious gastrointestinal diseases or related symptoms (such as nausea, vomiting, heartburn sensation or diarrhea), affected gastric emptying (such as pyloric stenosis), or had undergone any gastrointestinal surgery (except for intestinal polyp resection and appendectomy), or had acute diarrhea, constipation within the 7 days before randomization; Diarrhea is defined as watery stools and/or daily defecation ≥ 3 times. Constipation is defined as the inability to achieve at least one defecation per day;
    • (Medical Inquiry/Examination) During the screening, individuals with acute cholecystitis, chronic cholecystitis; or those with symptomatic or treatable gallstones at the time of screening; or those with symptomatic or treatable gallbladder polyps at the time of screening;
    • (Medical Inquiry) Individuals previously diagnosed with thyroid C-cell carcinoma, MEN (Multiple Endocrine Adenoma Disease) type 2A or 2B, or with a related family history;
    • (Medical Inquiry) Individuals previously diagnosed with acute or chronic pancreatitis, or pancreatic injury;
    • (Medical Inquiry/Query) Individuals who used any prescription drugs or over-the-counter drugs (including chemical drugs, vitamin drugs, herbal drugs, etc.) within 2 weeks before screening;
    • (Examination) Individuals with any positive results for surface antigen, virus antibody, antibody, or Treponema pallidum antibody during the screening period;
    • (Examination) At the screening/baseline, 12-lead shows a heart rate of \< 50 beats per minute or > 100 beats per minute, second or third degree atrioventricular conduction block, long syndrome or for women QTcF > 470 ms or for men > 450 ms or other electrocardiogram abnormalities judged by the investigator as requiring drug intervention;
    • (Medical Inquiry) Individuals with a history of fainting during blood transfusion or needle phobia;
    • (Medical Inquiry) Individuals who have taken drugs or had drug abuse history within 6 months before screening;
    • (Medical Inquiry) Individuals who smoked more than 10 cigarettes per day on average (including nicotine replacement products) within 3 months before screening, or who could not prohibit smoking throughout the trial stay;
    • (Medical Inquiry) Individuals who frequently drank alcohol within the 3 months before screening, that is, with an average daily alcohol intake of more than 2 units (1 unit = 17.7 mL ethanol, that is, 1 unit = 357 mL alcohol for 5% beer or 43 mL alcohol for 40% liquor or 147 mL alcohol for 12% wine) or who could not abstain from alcohol throughout the trial stay;
    • (Medical Inquiry) Individuals who donated blood or lost more than 400 mL of blood within 3 months before screening or plan to donate blood during or after the trial;
    • (Medical Inquiry/Query) Individuals who participated in drug or medical device clinical trials and received trial drugs (except for placebo) or medical device interventions within 3 months before screening;
    • (Medical Inquiry) Individuals who received any vaccine or plan to receive a vaccine during screening;
    • (Medical Inquiry/Examination) Female participants who are pregnant or lactating, or those with positive pregnancy test results during the screening period;
    • (Examination) Individuals with positive urine drug or alcohol breath screening at the baseline period;
    • Individuals determined by the investigator to be unsuitable to participate in this study or who withdrew from the study for personal reasons
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
144 participants (actual)

Study arms

  • Experimental
    BGM0504 tablets

    Oral administration once daily

    Drug: BGM0504 tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic (PK) endpoint: AUC0-tau,ss

    Time frame: 4 weeks

  2. PK endpoint:Cmax,ss

    Time frame: 4 weeks

  3. PK endpoint:t1/2,ss

    Time frame: 4 weeks

Secondary outcomes

  1. Pharmacodynamics (PD) endpoint:Changes in fasting blood glucose

    Time frame: 6 weeks

  2. PD endpoint:waist circumference before and after administration

    Time frame: 6 weeks

  3. PD endpoint:body weight before and after administration

    Time frame: 6 weeks

  4. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    Time frame: 6 weeks

  5. Number of participants with treatment-related serious adverse events as assessed by CTCAE v4.0

    Time frame: 6 weeks

07

Study locations

1 site
  • Hangzhou First People's Hospital
    Hangzhou, Zhejiang 310006, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Mar 2026 to primary completion in Aug 2026, 5 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Sep 2026 → Aug 2026 and completion Sep 2026 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
May 5, 2026
StartActual
Mar 26, 2026
Primary completionActual
Aug 31, 2026was Sep 2026
CompletionActual
Aug 31, 2026was Sep 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 13, 2026
Primary completion
Sep 30, 2026→Aug 31, 2026 (actual)
Oct 13, 2026
Study completion
Sep 30, 2026→Aug 31, 2026 (actual)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Recruiting→Completed
    Primary completion Sep 30, 2026→Aug 31, 2026 (now actual)
    Study completion Sep 30, 2026→Aug 31, 2026 (now actual)
    + 4 other changes: verification date, responsible party, site details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07566572
Responsible party
Sponsor
First posted
May 5, 2026
Start date
Mar 26, 2026
Primary completion
Aug 31, 2026
Completion
Aug 31, 2026
Last update
Oct 13, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BGM0504

Start the discussion